Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 25, 2026
DataAggregated Company Financials
Companies5
  • 7D-3.4%
  • 3M-24.2%
  • 1Y1.4%
  • YTD-20.5%

Over the last 7 days, the Biotech industry has dropped 3.4%, driven by Genmab declining 3.7%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 1.8% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 25 Mar 2026DKK 136.1bDKK 39.5bDKK 14.0b10.6x9.8x3.4x
Fri, 20 Feb 2026DKK 153.1bDKK 39.7bDKK 15.0b6.2x10.2x3.9x
Sun, 18 Jan 2026DKK 180.3bDKK 40.8bDKK 19.1b6.4x9.4x4.4x
Tue, 16 Dec 2025DKK 173.4bDKK 40.5bDKK 19.0b6x9.1x4.3x
Thu, 13 Nov 2025DKK 171.2bDKK 40.4bDKK 18.2b10.4x9.4x4.2x
Sat, 11 Oct 2025DKK 179.8bDKK 39.1bDKK 16.8b12.9x10.7x4.6x
Mon, 08 Sep 2025DKK 158.5bDKK 38.8bDKK 16.8b12.3x9.5x4.1x
Wed, 06 Aug 2025DKK 130.1bDKK 27.2bDKK 7.4b13x17.6x4.8x
Fri, 04 Jul 2025DKK 119.1bDKK 26.8bDKK 7.3b10.5x16.3x4.4x
Sun, 01 Jun 2025DKK 131.2bDKK 27.5bDKK 7.5b10.8x17.4x4.8x
Tue, 29 Apr 2025DKK 127.3bDKK 27.3bDKK 7.7b11.4x16.6x4.7x
Thu, 27 Mar 2025DKK 137.1bDKK 27.3bDKK 7.7b11.7x17.9x5x
Sat, 22 Feb 2025DKK 165.3bDKK 27.7bDKK 7.8b12.5x21.2x6x
Mon, 20 Jan 2025DKK 162.4bDKK 26.0bDKK 4.7b17.1x34.6x6.2x
Wed, 18 Dec 2024DKK 163.0bDKK 26.0bDKK 4.7b16.4x34.7x6.3x
Fri, 15 Nov 2024DKK 169.9bDKK 26.0bDKK 4.3b21.6x39.6x6.5x
Sun, 13 Oct 2024DKK 173.8bDKK 25.5bDKK 5.5b20.9x31.8x6.8x
Tue, 10 Sep 2024DKK 197.3bDKK 25.5bDKK 5.5b23.3x36.1x7.7x
Thu, 08 Aug 2024DKK 193.6bDKK 24.8bDKK 5.6b18.1x34.4x7.8x
Sat, 06 Jul 2024DKK 193.1bDKK 24.8bDKK 5.6b17.2x34.3x7.8x
Mon, 03 Jun 2024DKK 179.8bDKK 24.8bDKK 5.6b18.7x31.9x7.2x
Wed, 01 May 2024DKK 178.4bDKK 23.9bDKK 5.0b18.6x35.4x7.5x
Fri, 29 Mar 2024DKK 190.9bDKK 23.9bDKK 5.0b19.7x38x8x
Sun, 25 Feb 2024DKK 175.5bDKK 22.8bDKK 4.2b24.6x41.6x7.7x
Tue, 23 Jan 2024DKK 170.2bDKK 23.3bDKK 4.2b23.6x40.9x7.3x
Thu, 21 Dec 2023DKK 173.6bDKK 23.3bDKK 4.2b25.2x41.7x7.4x
Sat, 18 Nov 2023DKK 174.6bDKK 23.3bDKK 4.2b24.6x41.9x7.5x
Mon, 16 Oct 2023DKK 177.8bDKK 22.0bDKK 4.7b20.6x37.5x8.1x
Wed, 13 Sep 2023DKK 194.2bDKK 22.0bDKK 4.7b22.5x41.1x8.8x
Fri, 11 Aug 2023DKK 195.8bDKK 20.6bDKK 3.9b38.8x50.6x9.5x
Sun, 09 Jul 2023DKK 196.9bDKK 19.5bDKK 4.4b39.4x44.7x10.1x
Tue, 06 Jun 2023DKK 208.1bDKK 19.5bDKK 4.4b41.9x47.2x10.6x
Thu, 04 May 2023DKK 207.6bDKK 17.9bDKK 4.1b32.6x50.7x11.6x
Sat, 01 Apr 2023DKK 195.9bDKK 17.9bDKK 3.5b30.6x55.4x10.9x
Price to Earnings Ratio

55.4x


Total Market Cap: DKK 195.9bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 29.9x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.8x which is lower than its 3-year average PE of 29.9x.
  • The 3-year average PS ratio of 6.8x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 58% per year over the last three years.
  • Revenues for these companies have grown 30% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-4.18%
Healthcare-4.72%
Biotech-3.45%
Biotech-3.45%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
BAVA Bavarian NordicDKK 188.401.9%
+DKK 249.1m		18.2%PE10.6x
BIOPOR BioPortoDKK 0.912.3%
+DKK 9.9m		-36.5%PS12.3x

Latest News

BAVA
DKK 188.40
Bavarian Nordic
7D
1.9%
1Y
18.2%
BIOPOR
DKK 0.91
BioPorto
7D
2.3%
1Y
-36.5%
GMAB
DKK 1,649.00
Genmab
7D
-3.7%
1Y
24.7%

GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead

Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.
ZEAL
DKK 280.50
Zealand Pharma
7D
-5.7%
1Y
-50.4%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
STRAP
DKK 560.00
Strategic Partners
7D
-12.8%
1Y
-20.0%